Vernal Biosciences Announces Partnership With REPROCELL: Exclusive Distributorship in Japan for mRNA and LNP Formulation Services
11 July 2023
Vernal Biosciences, a leader in mRNA and LNP manufacturing, and REPROCELL Inc., Japan’s first induced pluripotent stem cell (iPSC) company, have partnered to provide mRNA services in Japan at scale for research and clinical applications
Joint Research Agreement with Keio University on Tumor-Infiltrating Lymphocyte Therapy for Cervical Cancer
28 June 2023
REPROCELL has entered into a joint research agreement with Keio University regarding the transfer of technology to produce Tumor Infiltrating Lymphocytes (TIL).
Simplifying AI data analysis for scientists – as REPROCELL, IBM and STFC Hartree Centre successfully launch Pharmacology-AI platform
01 June 2023
REPROCELL has collaborated with HNCDI to create a machine learning (ML) platform that simplifies and accelerates the analysis of big data from drug development studies.
[PRESS RELEASE] Announcement of Results of Phase II Clinical Trial in Japan for Stemchymal®, a Regenerative Medicine Product for Spinocerebellar Ataxia
25 May 2023
[PRESS RELEASE] Announcement of Results of Phase II Clinical Trial in Japan for Stemchymal®, a Regenerative Medicine Product for Spinocerebellar Ataxia
REPROCELL offers mesenchymal stem cell based CDMO services to manufacture Advanced Therapies Medicinal Products
23 May 2023
REPROCELL will now offer CDMO services to manufacture ATMPs generated from mesenchymal stem cells (MSC) through a partnership with Histocell.
End of Q4 update from REPROCELL (2022-23)
04 May 2023
Did you know that REPROCELL is celebrating its 20th anniversary this year? If you missed the commemorative letter from our CEO you can find out more here.
Lantern Pharma Selects REPROCELL USA to Provide Support for the Phase 2 Harmonic™ Clinical Trial
03 May 2023
REPROCELL USA has been awarded a contract to provide support for Lantern Pharma’s Phase 2 clinical trial entitled “HARMONIC”.
Celebrating the 20th Anniversary of REPROCELL: A letter from our CEO Chikafumi Yokoyama
28 February 2023
On February 26 2023 REPROCELL celebrated its 20th anniversary. In this letter, the company CEO reflects on the history of REPROCELL to the present day.
End of Q3 update from REPROCELL (2022-23)
12 December 2022
The final months of 2022 have brought new collaborations, partnerships, and successes to enrich your stem cell and drug discovery research.
Silo Pharma Initiates Study of Novel Joint Homing Peptide in Human Tissue
09 December 2022
The three-month study, conducted at REPROCELL, will assess the binding affinity of the peptide in healthy human and RA synovial tissue.
REPROCELL invests in Histocell, S.L. a Spain-based CDMO
23 November 2022
REPROCELL Inc. decided to invest in Histocell S.L. to strengthen its clinical induced pluripotent stem cell (iPSC) service offerings.
Building economic resilience and unleashing productivity through digital innovation
09 November 2022
CEO of REPROCELL said his company was among those that had received support from HNCDI to help it develop new approaches to drug development.
REPROCELL Inc. and JTB Corp. form a business alliance to provide Personal iPS Service to domestic and overseas customers
13 October 2022
REPROCELL Inc. and JTB Corp. will begin marketing Personal iPS (REPROCELL's iPSC storage and production service) overseas through the JMHC.
REPROCELL Inc. and CIRM sign MOU for special access to clinical iPSCs
05 October 2022
Learn why REPROCELL Inc. has agreed to join the California Institute for Regenerative Medicine’s (CIRM) Industry Resource Partner Program.
REPROCELL and BioBridge Global sign Memorandum of Understanding to accelerate global manufacturing services using clinical iPSCs
04 October 2022
REPROCELL and Texas-based BioBridge Global have signed a Memorandum of Understanding to enhance their strategic collaborative relationship. Find out more.
End of Q2 update from REPROCELL (2022-23)
03 October 2022
Read the end of Q2 update from REPROCELL for the financial year 2022-23. Discover the latest website updates, blog, and news updates.
REPROCELL, IBM and STFC harness the power of AI in drug discovery and precision medicine
31 August 2022
Collaboration at Hartree NCDI combines REPROCELL’s tests of drug efficacy in human living tissues with IBM expertise in AI and machine learning.
Preclinical studies by REPROCELL give COPD drug a final boost before clinical trials
17 August 2022
Learn how scientists at REPROCELL compared the effects of RCD405 with drugs that are currently used to treat respiratory disease in human living bronchi.
Life science after lockdown: SPS returns for 2022
15 August 2022
Discover the first, in-person Saftey Pharmacology Society annual meeting since 2019: a dynamic forum, known for its global networking opportunities.
Bioserve India granted NABL accreditation in the field of Genomics Testing
09 August 2022
Bioserve Biotechnologies India Pvt Ltd has received NABL accreditation for Medical Testing in the field of Genomics Testing Services.